Canopy Growth reported strong 27% growth in its medical marijuana division in Q4 fiscal 2026, but the rest of the business showed weakness. The recreational marijuana segment grew only 1% in Q4, international cannabis sales fell 7% year-over-year, and the Storz & Bickel vaporizer business declined 14%. The company continues to report negative earnings and faces declining gross margins, making it a risky investment despite one strong division.

Trulieve Cannabis Corp. became the first U.S. cannabis company to list on a major U.S. stock exchange (NYSE: TRLV), enabled by the Trump administration's reclassification of cannabis to Schedule III. The company separated its medical and adult-use operations to meet exchange requirements. Competitors like Curaleaf and Verano are preparing for similar uplistings, while Canadian producers remain on Nasdaq. The listing has energized the cannabis sector.

The DEA's rescheduling of marijuana from Schedule I to Schedule III in April 2026 was initially seen as historic but has had muted impact. The rescheduling only applies to medical marijuana and provides limited benefits like IRS Section 280E relief. Canopy Growth, a major Canadian cannabis company, cannot fully capitalize on these changes due to its non-controlling interest in its U.S. affiliate Canopy USA, whose results remain unconsolidated. The analyst concludes the rescheduling won't materially affect Canopy Growth soon and does not recommend the stock as a buy.

Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remains a risky penny stock in a struggling marijuana sector facing intense competition and illicit market pressures. Most investors should avoid the stock until it achieves sustainable profitability and the restatement is complete.

Canopy Growth has reduced debt and accumulated cash, but achieved this through significant share dilution. The company remains unprofitable even on an EBITDA basis. However, the recent acquisition of MTL Cannabis could create cost synergies and improve profitability. Investors are advised to wait for the May 29 earnings release before making investment decisions.

Canopy Growth shows early signs of stabilization after years of losses and restructuring, with narrowing EBITDA losses and 8% revenue growth in Canadian adult-use cannabis. However, investors remain divided on whether this represents a genuine turnaround or merely an extension of decline, given persistent industry oversupply, pricing pressure, and the company's continued unprofitability.

New federal cannabis tax rules are reshaping the industry with a split schedule that benefits medical-only operators while challenging multi-state operators. Medical-only companies like Trulieve could see faster margin and cash-flow improvements, while multi-state cannabis companies may face new tax-allocation hurdles that pressure near-term earnings.

Canopy Growth shares have surged 25% over the past month, but the article warns this may be a dead cat bounce. Despite recent positive moves like debt reduction and a medical marijuana acquisition, the company remains unprofitable since 2017 and faces significant headwinds from competition, regulation, and illicit market competition. The stock's penny status means large percentage gains can represent minimal dollar movements, and most investors should avoid it until profitability is proven.

Canopy Growth has lost 99.6% of its value over five years due to persistent profitability challenges, inability to enter the U.S. market directly, heavy cash burn, and shareholder dilution. While the stock could experience a dead cat bounce, long-standing issues and political gridlock limiting federal marijuana legalization make further downside possible. The article recommends financially stronger cannabis alternatives like Green Thumb Industries and Cronos Group, or marijuana ETFs, as better investment choices.

Canopy Growth, a Canadian marijuana leader, has plummeted 99% from its all-time high of $568 to around $1 per share. The company faces intense competition, has yet to achieve sustainable profitability, and is undertaking an acquisition that will dilute shareholders while weakening its balance sheet. Investors with significant losses may consider selling to harvest tax losses, as a return to previous highs seems unlikely in the near term.

Canopy Growth's stock has plummeted from over $300 to under $2 per share. Despite modest improvements in net loss per share, the company continues to post weak financial results with flat revenue and declining free cash flow. While recent cannabis reclassification in the U.S. offers some regulatory progress, the analyst argues the company faces insurmountable challenges including stiff competition, inability to transport cannabis across state lines, and failure to succeed even in the legalized Canadian market. The analyst concludes the stock is likely headed to $0 and recommends avoiding the investment.

Canopy Growth stock has collapsed from a peak of $568 per share to around $1.15, making it a money-losing penny stock with shareholder dilution concerns. The article suggests investors who bought at highs consider selling to harvest tax losses rather than holding onto the investment hoping for a recovery, as the marijuana sector enthusiasm has significantly cooled.